This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 3484 |
mean age | 2688 |
risk factors | 2368 |
control group | 2292 |
mg kg | 2166 |
care unit | 2003 |
significantly higher | 1965 |
critically ill | 1756 |
two groups | 1745 |
significant difference | 1745 |
present study | 1729 |
statistically significant | 1726 |
blood pressure | 1665 |
mechanical ventilation | 1608 |
septic shock | 1480 |
systematic review | 1470 |
health care | 1459 |
ng ml | 1441 |
gene expression | 1406 |
significant differences | 1392 |
ill patients | 1329 |
years old | 1308 |
results suggest | 1306 |
amino acid | 1239 |
one patient | 1219 |
breast cancer | 1211 |
bone marrow | 1206 |
cell lines | 1198 |
patients admitted | 1190 |
blood donors | 1138 |
performed using | 1130 |
amino acids | 1090 |
acute respiratory | 1083 |
adverse events | 1070 |
clinical trials | 1063 |
critical care | 1057 |
mental health | 1032 |
logistic regression | 1031 |
important role | 1014 |
university hospital | 1007 |
cohort study | 1003 |
case report | 1001 |
mg dl | 999 |
cardiac arrest | 981 |
study design | 980 |
blood transfusion | 969 |
whole blood | 966 |
median age | 946 |
increased risk | 940 |
brain injury | 940 |
significantly lower | 934 |
signifi cant | 928 |
public health | 927 |
epithelial cells | 925 |
blood samples | 924 |
pg ml | 924 |
side effects | 923 |
body weight | 922 |
cystic fibrosis | 911 |
united states | 905 |
flow cytometry | 897 |
risk factor | 882 |
retrospective study | 880 |
statistical analysis | 880 |
patients undergoing | 862 |
blood flow | 851 |
emergency department | 848 |
peripheral blood | 844 |
high risk | 841 |
patients received | 836 |
red blood | 836 |
mortality rate | 831 |
two patients | 831 |
patients treated | 828 |
least one | 827 |
significantly increased | 824 |
immune response | 819 |
lymph node | 816 |
lung cancer | 816 |
lymph nodes | 810 |
stem cells | 809 |
hospital stay | 806 |
renal failure | 802 |
nervous system | 797 |
oxidative stress | 792 |
prospective study | 788 |
clinical practice | 785 |
study period | 779 |
cell line | 770 |
stem cell | 760 |
hospital mortality | 759 |
respiratory failure | 756 |
lung function | 740 |
data suggest | 734 |
clinical trial | 731 |
controlled trial | 726 |
long term | 722 |
urinary tract | 721 |
observational study | 721 |
patients underwent | 717 |
may also | 717 |
design method | 707 |
signifi cantly | 704 |
spinal cord | 699 |
inclusion criteria | 698 |
adult patients | 696 |
significant increase | 691 |
regression analysis | 687 |
randomized controlled | 685 |
respiratory tract | 682 |
icu admission | 680 |
year old | 677 |
inflammatory response | 674 |
extracellular vesicles | 672 |
renal function | 671 |
heart failure | 670 |
results indicate | 668 |
computed tomography | 661 |
cell proliferation | 659 |
growth factor | 657 |
determine whether | 657 |
pregnant women | 656 |
apache ii | 655 |
previous studies | 655 |
cancer patients | 654 |
diabetes mellitus | 648 |
respiratory distress | 643 |
ct scan | 643 |
heart rate | 643 |
icu patients | 641 |
consecutive patients | 640 |
western blot | 638 |
significantly reduced | 636 |
weight loss | 636 |
blood cells | 636 |
electron microscopy | 635 |
medical center | 631 |
patients without | 631 |
immune system | 631 |
ml min | 628 |
sample size | 628 |
smooth muscle | 619 |
cancer cells | 615 |
mg ml | 614 |
organ failure | 611 |
informed consent | 610 |
endothelial cells | 602 |
significantly different | 602 |
three patients | 601 |
cardiac surgery | 601 |
fi ndings | 598 |
prostate cancer | 589 |
differential diagnosis | 588 |
protein expression | 584 |
blood cell | 584 |
adverse effects | 583 |
measured using | 582 |
icu stay | 582 |
mrna expression | 578 |
case studies | 578 |
multivariate analysis | 577 |
results show | 576 |
patients receiving | 575 |
two different | 575 |
present document | 571 |
cell death | 571 |
summary conclusion | 570 |
among patients | 570 |
lung disease | 570 |
body mass | 570 |
image quality | 569 |
blood products | 568 |
magnetic resonance | 566 |
identifi ed | 565 |
trauma patients | 563 |
severe sepsis | 561 |
blood components | 561 |
type diabetes | 561 |
ml kg | 561 |
within hours | 560 |
older adults | 560 |
lung injury | 559 |
healthy controls | 559 |
commonly used | 553 |
physical activity | 552 |
significantly associated | 552 |
staphylococcus aureus | 546 |
cell surface | 546 |
pilot study | 546 |
one year | 542 |
care units | 540 |
infectious diseases | 539 |
kg day | 539 |
data collection | 538 |
age years | 536 |
coronary artery | 536 |
red cell | 535 |
nitric oxide | 535 |
blood donation | 534 |
first time | 533 |
predictive value | 531 |
abdominal pain | 530 |
central venous | 529 |
outcome measures | 528 |
old male | 525 |
traumatic brain | 521 |
pediatric patients | 521 |
blood loss | 517 |
blood group | 511 |
mass spectrometry | 508 |
results showed | 508 |
year period | 507 |
minimally invasive | 505 |
analysis showed | 503 |
central nervous | 503 |
mass index | 501 |
wild type | 500 |
type i | 499 |
widely used | 499 |
tumor cells | 499 |
metabolic syndrome | 498 |
pet ct | 497 |
medical records | 493 |
heart disease | 490 |
summary conclusions | 490 |
hand hygiene | 486 |
one case | 483 |
odds ratio | 482 |
blood glucose | 481 |
background case | 481 |
four patients | 478 |
factors associated | 478 |
clinical signs | 478 |
soft tissue | 477 |
included patients | 477 |
primary outcome | 473 |
recent studies | 470 |
myocardial infarction | 470 |
multiple sclerosis | 468 |
findings suggest | 468 |
study group | 468 |
total number | 461 |
significantly decreased | 460 |
cell types | 459 |
may contribute | 459 |
fi rst | 456 |
clinical data | 453 |
ischemic stroke | 451 |
study aimed | 451 |
colorectal cancer | 450 |
primary care | 449 |
cord uid | 449 |
doc id | 449 |
animal models | 448 |
preliminary results | 448 |
cd cd | 447 |
time pcr | 447 |
healthcare workers | 447 |
social media | 446 |
kidney disease | 445 |
insulin resistance | 443 |
distress syndrome | 440 |
mechanically ventilated | 440 |
month period | 439 |
retrospective analysis | 439 |
immune responses | 439 |
blood bank | 438 |
high levels | 438 |
average age | 435 |
systematic reviews | 434 |
last years | 434 |
may lead | 433 |
general population | 432 |
platelet count | 429 |
severe acute | 428 |
significant correlation | 427 |
cell carcinoma | 427 |
analysis revealed | 426 |
liver disease | 426 |
previously reported | 425 |
healthy volunteers | 421 |
clinical outcomes | 421 |
day mortality | 420 |
septic patients | 420 |
five patients | 419 |
food safety | 417 |
old female | 417 |
study showed | 416 |
clinical studies | 414 |
time points | 414 |
tract infections | 413 |
left ventricular | 412 |
statistical significance | 412 |
wide range | 411 |
plasma membrane | 411 |
one study | 410 |
arterial blood | 408 |
also found | 407 |
physical examination | 407 |
patient care | 407 |
included studies | 406 |
analyzed using | 406 |
family members | 405 |
pseudomonas aeruginosa | 405 |
may play | 405 |
antibiotic therapy | 405 |
group i | 405 |
significant reduction | 401 |
aft er | 401 |
disease severity | 399 |
current study | 399 |
assessed using | 399 |
significant decrease | 398 |
within days | 397 |
exclusion criteria | 397 |
mouse model | 394 |
per patient | 393 |
safety authority | 393 |
clinical features | 393 |
european food | 393 |
gold standard | 392 |
chronic hepatitis | 392 |
serum levels | 392 |
linear regression | 390 |
small bowel | 390 |
molecular mechanisms | 388 |
cell cycle | 388 |
real time | 388 |
replacement therapy | 388 |
recent years | 387 |
confidence interval | 386 |
two cases | 385 |
sectional study | 382 |
white matter | 381 |
molecular weight | 380 |
case series | 380 |
inflammatory cytokines | 379 |
positive correlation | 378 |
cardiac output | 378 |
results finding | 377 |
arterial pressure | 377 |
patients showed | 377 |
chain reaction | 377 |
expression levels | 376 |
mortality rates | 376 |
adipose tissue | 375 |
three groups | 375 |
infection control | 372 |
respiratory syndrome | 369 |
large number | 369 |
coronavirus disease | 369 |
age group | 369 |
imaging findings | 368 |
study included | 368 |
poor outcome | 367 |
dependent manner | 367 |
polymerase chain | 366 |
united kingdom | 364 |
transcription factor | 364 |
standard deviation | 364 |
controlled trials | 363 |
per day | 363 |
cardiovascular disease | 363 |
escherichia coli | 361 |
per year | 360 |
health services | 360 |
may provide | 360 |
reactive protein | 359 |
higher risk | 357 |
tract infection | 357 |
type ii | 356 |
cancer cell | 356 |
ii score | 355 |
hbv dna | 355 |
fatty acids | 352 |
main outcome | 352 |
determined using | 352 |
allergic rhinitis | 351 |
skeletal muscle | 351 |
may help | 351 |
resonance imaging | 351 |
even though | 350 |
clinically relevant | 350 |
well tolerated | 350 |
retrospective review | 349 |
prospective cohort | 349 |
clinical outcome | 348 |
organ dysfunction | 348 |
patients presenting | 347 |
quality control | 346 |
chart review | 346 |
sofa score | 345 |
neurocritical care | 344 |
old woman | 344 |
transfusion medicine | 344 |
six patients | 343 |
pulmonary artery | 342 |
infectious disease | 341 |
pulmonary disease | 341 |
animal model | 341 |
gastric cancer | 340 |
abstract background | 339 |
three different | 338 |
air pollution | 337 |
will also | 336 |
data analysis | 335 |
subarachnoid hemorrhage | 335 |
kidney injury | 335 |
different types | 334 |
elderly patients | 334 |
dendritic cells | 333 |
mr imaging | 332 |
healthy subjects | 332 |
renal disease | 330 |
serum creatinine | 329 |
well known | 328 |
extracellular matrix | 328 |
iu ml | 328 |
surgical treatment | 326 |
clinically significant | 325 |
group ii | 325 |
diagnostic accuracy | 325 |
one hundred | 324 |
control study | 324 |
ex vivo | 324 |
infl ammatory | 323 |
study population | 321 |
clinical course | 321 |
retrospective cohort | 320 |
rheumatoid arthritis | 320 |
commercially available | 319 |
control groups | 319 |
cell culture | 319 |
pulmonary function | 319 |
age groups | 319 |
overall survival | 318 |
high dose | 318 |
higher levels | 316 |
may result | 316 |
red cells | 315 |
monoclonal antibodies | 315 |
prospective observational | 315 |
specific ige | 315 |
necrosis factor | 314 |
seven patients | 314 |
hospital discharge | 313 |
plasma levels | 313 |
two years | 313 |
lg ml | 312 |
acute lung | 312 |
evaluated using | 312 |
six months | 311 |
also observed | 310 |
respiratory infections | 310 |
world health | 309 |
monoclonal antibody | 308 |
family history | 307 |
renal replacement | 306 |
clinical characteristics | 305 |
birth weight | 305 |
high resolution | 305 |
blood donor | 305 |
showed significant | 305 |
gestational age | 304 |
several studies | 304 |
innate immune | 304 |
blood cultures | 304 |
univariate analysis | 303 |
high level | 303 |
mean arterial | 303 |
acute kidney | 303 |
two studies | 302 |
study will | 301 |
postoperative complications | 301 |
acute renal | 301 |
cd cells | 301 |
study aims | 301 |
th day | 300 |
positive cells | 300 |
young children | 300 |
operative time | 298 |
viral infections | 298 |
new york | 297 |
decision making | 297 |
cohort studies | 296 |
critical illness | 296 |
mononuclear cells | 295 |
surgical intervention | 294 |
class i | 293 |
clinical symptoms | 293 |
multiple organ | 293 |
hospitalized patients | 293 |
ventilated patients | 292 |
general hospital | 291 |
future studies | 291 |
significant improvement | 291 |
learning objectives | 291 |
studies showed | 291 |
observational studies | 291 |
ct scans | 291 |
regression model | 290 |
three months | 290 |
medical history | 290 |
taken together | 290 |
results demonstrate | 289 |
low dose | 289 |
protein levels | 288 |
data indicate | 288 |
old man | 288 |
literature review | 287 |
reactive oxygen | 287 |
independently associated | 287 |
demographic data | 287 |
significant association | 287 |
data collected | 287 |
early diagnosis | 285 |
eight patients | 285 |
viral load | 285 |
patients presented | 285 |
high quality | 285 |
retrospectively reviewed | 285 |
median time | 285 |
patients aged | 284 |
study shows | 284 |
mesenchymal stem | 284 |
laparoscopic surgery | 284 |
may occur | 283 |
acute phase | 283 |
key role | 283 |
patients died | 282 |
results obtained | 282 |
clinical presentation | 281 |
previously described | 281 |
patient population | 280 |
mast cells | 280 |
western blotting | 280 |
bariatric surgery | 279 |
positive results | 278 |
tidal volume | 278 |
gastrointestinal tract | 277 |
tumor necrosis | 275 |
intervention group | 275 |
hepatocellular carcinoma | 274 |
pulmonary embolism | 274 |
survival rate | 274 |
may cause | 274 |
sickle cell | 274 |
nephrotic syndrome | 273 |
first hours | 273 |
see table | 272 |
biological activity | 271 |
status epilepticus | 271 |
cytokine production | 271 |
binding site | 270 |
fold increase | 270 |
defi ned | 270 |
control subjects | 269 |
teaching hospital | 269 |
high mortality | 269 |
small intestine | 269 |
immune cells | 269 |
respiratory symptoms | 269 |
research funds | 268 |
tertiary care | 268 |
bile duct | 268 |
infl ammation | 268 |
significant changes | 267 |
treatment group | 267 |
nucleic acid | 267 |
investigate whether | 267 |
protein kinase | 266 |
one week | 266 |
oxygen saturation | 265 |
squamous cell | 265 |
binding protein | 265 |
analysed using | 265 |
pao fio | 264 |
disease progression | 263 |
high prevalence | 263 |
blood volume | 263 |
case reports | 262 |
age range | 262 |
molecular dynamics | 262 |
days post | 262 |
nine patients | 262 |
mrna levels | 262 |
older people | 261 |
national institute | 261 |
preliminary data | 261 |
blot analysis | 261 |
response rate | 260 |
fatty acid | 260 |
prognostic factors | 259 |
hcv rna | 259 |
oxygen species | 258 |
health outcomes | 258 |
serum samples | 258 |
data show | 258 |
colon cancer | 258 |
treated patients | 257 |
poorly understood | 257 |
leading cause | 257 |
one month | 257 |
functional outcome | 257 |
dna damage | 256 |
infected patients | 255 |
cell adhesion | 255 |
chronic kidney | 255 |
muscle mass | 255 |
diabetic patients | 255 |
also showed | 255 |
please specify | 254 |
confl ict | 254 |
patients diagnosed | 254 |
abstract type | 254 |
analysis using | 254 |
differentially expressed | 253 |
cognitive impairment | 253 |
surgical procedures | 253 |
signal transduction | 253 |
health organization | 253 |
fl uid | 252 |
early detection | 252 |
whole body | 252 |
normal range | 252 |
graduate school | 252 |
patients developed | 252 |
aged years | 251 |
correlation coefficient | 251 |
small number | 251 |
adverse event | 250 |
common cause | 250 |
associated pneumonia | 250 |
cell activation | 249 |
first step | 249 |
hospital admission | 249 |
transcription factors | 249 |
respiratory rate | 248 |
transfusion reactions | 248 |
patient safety | 248 |
severe asthma | 248 |
novel coronavirus | 248 |
platelet concentrates | 247 |
patients may | 247 |
studies using | 247 |
gene therapy | 247 |
icu mortality | 246 |
children aged | 246 |
blood gas | 246 |
protective effect | 245 |
poor prognosis | 245 |
laparoscopic approach | 245 |
fl ow | 245 |
brain tissue | 245 |
chronic obstructive | 244 |
increased significantly | 244 |
acquired pneumonia | 243 |
patients suffering | 243 |
mean duration | 241 |
lower respiratory | 241 |
months later | 241 |
mg day | 241 |
two weeks | 241 |
palliative care | 240 |
intracranial pressure | 239 |
success rate | 239 |
ethics regulations | 239 |
transgenic mice | 239 |
rectal cancer | 239 |
better understanding | 239 |
gel electrophoresis | 238 |
studies suggest | 238 |
risk assessment | 238 |
will provide | 238 |
radiation dose | 238 |
antibiotic treatment | 238 |
postoperative day | 238 |
cell membrane | 238 |
randomised controlled | 237 |
collected data | 237 |
cardiovascular risk | 237 |
calculated using | 237 |
diagnostic criteria | 237 |
retrospective chart | 236 |
viral infection | 236 |
study conducted | 235 |
first trimester | 235 |
chest pain | 235 |
uric acid | 235 |
compared using | 234 |
plasma samples | 234 |
increased mortality | 234 |
patient outcomes | 234 |
artery disease | 234 |
cell viability | 234 |
false positive | 234 |
case study | 233 |
data will | 233 |
placebo group | 233 |
medical university | 233 |
may represent | 232 |
liver injury | 232 |
blood supply | 231 |
clinical findings | 230 |
medical treatment | 230 |
cell count | 230 |
growth factors | 230 |
quality improvement | 230 |
respiratory disease | 230 |
treatment groups | 230 |
negative predictive | 229 |
low risk | 228 |
surgical patients | 228 |
wound healing | 228 |
connective tissue | 228 |
health status | 228 |
group compared | 228 |
nutritional status | 227 |
mm hg | 227 |
studies reported | 227 |
pulmonary hypertension | 227 |
progenitor cells | 226 |
patients will | 226 |
scoring system | 226 |
remains unclear | 225 |
time point | 225 |
saps ii | 225 |
confidence intervals | 225 |
high frequency | 225 |
liver transplantation | 225 |
time period | 225 |
first days | 225 |
binding sites | 224 |
wistar rats | 224 |
nosocomial infections | 223 |
antimicrobial resistance | 223 |
higher mortality | 222 |
endothelial cell | 222 |
obstructive pulmonary | 222 |
copd patients | 222 |
virus infection | 221 |
gastric bypass | 221 |
less likely | 221 |
bronchoalveolar lavage | 221 |
lung tissue | 221 |
obese patients | 220 |
blood vessels | 220 |
white blood | 220 |
deficient mice | 220 |
early stage | 220 |
low levels | 220 |
platelet aggregation | 219 |
randomly assigned | 219 |
increased expression | 219 |
study protocol | 219 |
patients included | 217 |
broad spectrum | 216 |
study suggests | 216 |
adverse reactions | 215 |
ethics committee | 215 |
secondary outcomes | 215 |
developing countries | 214 |
room temperature | 214 |
independent risk | 214 |
solid phase | 214 |
young adults | 214 |
glasgow coma | 214 |
chronic inflammatory | 214 |
high incidence | 213 |
airway pressure | 213 |
systolic blood | 213 |
also performed | 212 |
liver function | 212 |
carotid artery | 212 |
similar results | 212 |
signaling pathways | 212 |
blood collection | 212 |
muscle cells | 211 |
airway epithelial | 211 |
significantly greater | 211 |
transplant recipients | 211 |
nuclear medicine | 210 |
significantly improved | 210 |
ejection fraction | 210 |
upper respiratory | 210 |
food allergy | 209 |
glucose tolerance | 209 |
function tests | 209 |
combination therapy | 209 |
adhesion molecules | 208 |
transfusion service | 208 |
prospective studies | 208 |
three cases | 208 |
epithelial cell | 208 |
previous study | 207 |
active site | 207 |
term follow | 207 |
receptor antagonist | 206 |
times higher | 206 |
may affect | 206 |
square test | 206 |
first year | 206 |
test results | 206 |
randomized clinical | 205 |
primary endpoint | 205 |
crucial role | 205 |
previously shown | 205 |
genomic dna | 205 |
fold higher | 204 |
airway inflammation | 204 |
effective treatment | 204 |
brain death | 204 |
abdominal wall | 204 |
baseline characteristics | 203 |
clinical examination | 203 |
complication rate | 203 |
social support | 203 |
patient underwent | 203 |
years ago | 203 |
serum albumin | 203 |
data sets | 203 |
blood banks | 203 |
specific antibodies | 202 |
cerebrospinal fluid | 202 |
will help | 202 |
three times | 202 |
blood culture | 201 |
year follow | 201 |
venous blood | 201 |
treatment options | 201 |
inflammatory bowel | 201 |
therapeutic hypothermia | 201 |
ko mice | 200 |
descriptive statistics | 200 |
study using | 200 |
least two | 200 |
inhibitory effect | 200 |
overall mortality | 200 |
severe covid | 200 |
beneficial effects | 200 |
nucleic acids | 200 |
significantly correlated | 200 |
care medicine | 200 |
vital signs | 200 |
studies included | 199 |
inflammatory mediators | 199 |
useful tool | 199 |
patients requiring | 199 |
relative risk | 198 |
exact test | 198 |
medical care | 198 |
situ hybridization | 198 |
well established | 198 |
asthma control | 198 |
postoperative period | 198 |
positive patients | 198 |
critical role | 197 |
positive predictive | 197 |
free survival | 197 |
will allow | 196 |
better understand | 196 |
randomly selected | 196 |
plasma concentrations | 195 |
machine learning | 195 |
clinical improvement | 195 |
protein synthesis | 195 |
regression models | 195 |
issues addressed | 195 |
drug resistance | 195 |
patients required | 195 |
factor viii | 195 |
chronic inflammation | 194 |
fdg pet | 194 |
three days | 194 |
another study | 194 |
conclusions reached | 194 |
cell type | 194 |
patient characteristics | 194 |
cell cultures | 194 |
authority reserves | 194 |
kg min | 194 |
published complying | 193 |
increased levels | 193 |
past years | 193 |
transparency principle | 193 |
clinical study | 193 |
output adopted | 193 |
controlled study | 193 |
awarded following | 193 |
surface area | 193 |
acute pancreatitis | 193 |
patients compared | 193 |
tender procedure | 193 |
high affinity | 193 |
much higher | 193 |
clinical use | 192 |
significant effect | 192 |
investigated whether | 192 |
disease activity | 192 |
mean value | 192 |
time spent | 192 |
may reduce | 192 |
interquartile range | 191 |
general anesthesia | 191 |
expression level | 191 |
ten patients | 191 |
liver cirrhosis | 191 |
risk patients | 190 |
bacterial infection | 190 |
mechanisms underlying | 190 |
mean time | 190 |
high grade | 190 |
differ significantly | 189 |
vitro studies | 189 |
clinical diagnosis | 189 |
data obtained | 189 |
body composition | 189 |
mean difference | 188 |
medical students | 188 |
medical record | 188 |
inflammatory diseases | 188 |
cell migration | 188 |
inflammatory responses | 188 |
also known | 188 |
ms ms | 188 |
medical school | 188 |
without prejudice | 188 |
healthy individuals | 188 |
laboratory tests | 188 |
otitis media | 188 |
atopic dermatitis | 187 |
many patients | 187 |
evidence suggests | 187 |
cell disease | 187 |
copies ml | 187 |
three studies | 187 |
major cause | 187 |
blood donations | 187 |
tyrosine kinase | 187 |
influenza virus | 187 |
male patients | 187 |
chronic disease | 187 |
closely related | 186 |
radiation exposure | 186 |
bowel disease | 186 |
ovarian cancer | 185 |
transmission electron | 185 |
naturally occurring | 185 |
bodies identified | 185 |
blood units | 185 |
studies will | 184 |
phase i | 184 |
clinical isolates | 184 |
study demonstrates | 184 |
month follow | 184 |
parenteral nutrition | 184 |
prognostic value | 184 |
female patients | 184 |
trauma center | 183 |
spatial resolution | 183 |
many studies | 183 |
inflammatory cells | 183 |
general surgery | 183 |
respiratory viruses | 183 |
severity score | 182 |
blood mononuclear | 182 |
odds ratios | 182 |
liver failure | 182 |
examination revealed | 182 |
using two | 182 |
activated protein | 181 |
survival rates | 181 |
atrial fibrillation | 181 |
weight gain | 181 |
lupus erythematosus | 181 |
internal medicine | 181 |
renal biopsy | 181 |
recent study | 181 |
cd expression | 181 |
ca i | 181 |
may improve | 181 |
respiratory syncytial | 181 |
vast majority | 181 |
chronic renal | 181 |
sleeve gastrectomy | 181 |
using different | 180 |
early stages | 180 |
cfu ml | 180 |
signaling pathway | 180 |
hypertonic saline | 180 |
receiver operating | 180 |
randomized trial | 180 |
stromal cells | 180 |
hernia repair | 180 |
confi rmed | 180 |
mouse models | 180 |
invasive ventilation | 180 |
cell responses | 179 |
mean values | 179 |
also used | 179 |
intracerebral hemorrhage | 179 |
single dose | 179 |
chronic diseases | 179 |
blood product | 179 |
high doses | 179 |
head injury | 179 |
surgical procedure | 179 |
enzyme activity | 178 |
negative correlation | 178 |
environmental factors | 178 |
peer review | 178 |
months post | 178 |
glial cells | 178 |
syncytial virus | 178 |
blood center | 178 |
clinical setting | 178 |
cardiac index | 178 |
icu discharge | 177 |
signal intensity | 177 |
methods materials | 177 |
related complications | 177 |
cells expressing | 177 |
significantly less | 177 |
systemic lupus | 177 |
strongly associated | 177 |
major role | 177 |
dawley rats | 177 |
study found | 177 |
days later | 177 |
proinflammatory cytokines | 177 |
hours post | 177 |
urine samples | 177 |
cord blood | 176 |
hiv infection | 176 |
cell lymphoma | 176 |
cerebral edema | 176 |
health problem | 176 |
small cell | 176 |
time course | 176 |
also significantly | 175 |
prospectively collected | 175 |
nk cells | 175 |
cell transplantation | 175 |
first study | 175 |
antibiotic resistance | 175 |
higher incidence | 175 |
cerebral blood | 174 |
medical staff | 174 |
wide variety | 174 |
right ventricular | 174 |
phase ii | 174 |
assess whether | 174 |
care workers | 174 |
vena cava | 173 |
mean follow | 173 |
living cells | 173 |
glomerular filtration | 173 |
imaging techniques | 173 |
university medical | 173 |
positively correlated | 173 |
considered significant | 173 |
class ii | 172 |
operation time | 172 |
short term | 172 |
rat model | 172 |
acute ischemic | 172 |
respiratory system | 172 |
significant change | 172 |
health problems | 172 |
study participants | 171 |
may influence | 171 |
stage renal | 171 |
drug administration | 171 |
knockout mice | 171 |
may reflect | 171 |
extremely rare | 171 |
glucose levels | 171 |
tumor size | 171 |
total protein | 170 |
streptococcus pneumoniae | 170 |
vascular endothelial | 170 |
mast cell | 170 |
diffi cult | 170 |
renal transplantation | 170 |
congenital heart | 170 |
care patients | 170 |
results will | 170 |
gas exchange | 170 |
confocal microscopy | 170 |
roc curve | 170 |
generation sequencing | 170 |
serious adverse | 170 |
potential role | 170 |
antimicrobial activity | 170 |
patients using | 170 |
injury severity | 169 |
decreased significantly | 169 |
fat diet | 169 |
bacterial infections | 169 |
remaining patients | 168 |
cell growth | 168 |
inhibitory activity | 168 |
single center | 168 |
pulmonary edema | 168 |
future research | 167 |
statistical difference | 167 |
neuropathic pain | 167 |
first case | 167 |
took place | 167 |
infl uence | 167 |
trend towards | 167 |
renal transplant | 167 |
low molecular | 167 |
patient presented | 167 |
mitral valve | 167 |
newly diagnosed | 167 |
statistical analyses | 167 |
drug delivery | 167 |
animal studies | 167 |
new zealand | 167 |
high sensitivity | 166 |
liquid chromatography | 166 |
mixed methods | 166 |
healthcare professionals | 166 |
fresh frozen | 166 |
pleural effusion | 166 |
tissue samples | 166 |
acute care | 166 |
imaging modalities | 166 |
disease control | 165 |
selected patients | 165 |
fdg uptake | 165 |
emergency room | 165 |
body temperature | 165 |
schwann cells | 165 |
statistically signifi | 165 |
patient age | 165 |
oral health | 165 |
nerve conduction | 165 |
skin prick | 165 |
lipid peroxidation | 165 |
negative bacteria | 164 |
derived evs | 164 |
peripheral nerve | 164 |
median follow | 164 |
obtained using | 164 |
conformational changes | 164 |
emergency medicine | 164 |
secondary structure | 164 |
cells showed | 164 |
surgical resection | 164 |
ards patients | 163 |
resistant staphylococcus | 163 |
autoimmune diseases | 163 |
elevated levels | 163 |
literature search | 163 |
dna methylation | 163 |
low grade | 163 |
outcome measure | 162 |
final diagnosis | 162 |
steady state | 162 |
research institute | 162 |
natural history | 162 |
quantitative analysis | 162 |
old girl | 162 |
brain barrier | 161 |
hospital cardiac | 161 |
bacterial contamination | 161 |
tumor growth | 161 |
molecular biology | 161 |
patients hospitalized | 161 |
frozen plasma | 161 |
clinical significance | 161 |
allowed us | 161 |
systemic inflammatory | 161 |
patient satisfaction | 161 |
flow rate | 161 |
cell lung | 160 |
plant mirnas | 160 |
multivariate logistic | 160 |
peripheral neuropathy | 160 |
liver biopsy | 160 |
scanning electron | 160 |
coma scale | 159 |
genes involved | 159 |
groups according | 159 |
group received | 159 |
total rna | 159 |
study also | 159 |
tissue damage | 159 |
gram negative | 159 |
identified using | 159 |
frequently used | 159 |
also reported | 159 |
membrane proteins | 159 |
culture medium | 158 |
hearing loss | 158 |
serum concentrations | 158 |
optic nerve | 158 |
term outcomes | 158 |
clinical research | 158 |
three years | 158 |
cerebral ischemia | 157 |
lactate levels | 157 |
design methods | 157 |
oral administration | 157 |
clinical manifestations | 157 |
hydrogen peroxide | 157 |
fluorescence microscopy | 157 |
new therapeutic | 157 |
pulmonary fibrosis | 157 |
blood gases | 157 |
protein level | 157 |
creatinine clearance | 157 |
data demonstrate | 157 |
cardiac function | 156 |
filtration rate | 156 |
significantly elevated | 156 |
adhesion molecule | 156 |
nursing staff | 156 |
five years | 156 |
beneficial effect | 156 |
clostridium difficile | 156 |
positive samples | 156 |
venous catheter | 156 |
last decade | 156 |
endoplasmic reticulum | 156 |
using standard | 155 |
may increase | 155 |
comparative study | 155 |
laparoscopic cholecystectomy | 155 |
acute appendicitis | 155 |
one hour | 155 |
venous thrombosis | 155 |
four groups | 155 |
stroke patients | 155 |
ct angiography | 155 |
among children | 154 |
positive control | 154 |
neurodegenerative diseases | 154 |
muscle strength | 154 |
information regarding | 154 |
icu length | 154 |
intracranial hemorrhage | 154 |
pathogen avoidance | 154 |
acute rejection | 154 |
health professionals | 154 |
abdominal surgery | 153 |
neurological outcome | 153 |
acute myocardial | 153 |
done using | 153 |
clinical management | 153 |
healthy control | 153 |
will discuss | 153 |
hospital length | 153 |
potential therapeutic | 153 |
mean number | 153 |
patient developed | 153 |
currently available | 153 |
mcg ml | 153 |
clinical response | 153 |
resistant strains | 153 |
conducted using | 153 |
data showed | 153 |
clinical relevance | 153 |
target cells | 152 |
research abstract | 152 |
waist circumference | 152 |
venous catheters | 152 |
patient demographics | 152 |
study demonstrated | 152 |
central role | 152 |
states background | 152 |
clinical information | 152 |
model system | 151 |
present work | 151 |
carbon dioxide | 151 |
binding proteins | 151 |
two types | 151 |
conservative treatment | 151 |
two independent | 151 |
electronic medical | 151 |
diff erence | 151 |
relatively low | 150 |
independent predictor | 150 |
healthy dogs | 150 |
contrast enhancement | 150 |
higher rate | 150 |
high rate | 150 |
may explain | 150 |
treated cells | 150 |
rank test | 150 |
syndrome coronavirus | 149 |
healthy donors | 149 |
gi tract | 149 |
european countries | 149 |
th percentile | 149 |
incidence rate | 149 |
chronic pain | 149 |
findings indicate | 149 |
identify patients | 149 |
cerebral artery | 149 |
old boy | 149 |
severe tbi | 149 |
i will | 148 |
body fat | 148 |
blood sample | 148 |
see chapter | 148 |
inflammatory cytokine | 148 |
membrane potential | 148 |
laboratory animals | 148 |
table shows | 148 |
pediatric population | 148 |
second group | 148 |
hematopoietic stem | 148 |
tumour cells | 147 |
may serve | 147 |
university school | 147 |
group showed | 147 |
twice daily | 147 |
th ere | 147 |
next generation | 147 |
national health | 147 |
within minutes | 147 |
potential risk | 147 |
important factor | 146 |
antibiotic use | 146 |
operating room | 146 |
red cross | 146 |
innate immunity | 146 |
published data | 146 |
antimicrobial therapy | 146 |
quality assurance | 146 |
chest ct | 146 |
results findings | 146 |
four different | 146 |
two methods | 146 |
routine use | 146 |
clinical parameters | 146 |
cardiovascular diseases | 146 |
antimicrobial agents | 145 |
inflammatory markers | 145 |
male patient | 145 |
protective equipment | 145 |
laboratory data | 145 |
shock patients | 145 |
autosomal recessive | 145 |
portal vein | 145 |
platelet counts | 145 |
small sample | 145 |
higher rates | 145 |
additional information | 144 |
author funder | 144 |
bladder cancer | 144 |
high degree | 144 |
imaging modality | 144 |
term outcome | 144 |
multicenter study | 144 |
female patient | 144 |
histological examination | 144 |
patient group | 144 |
granted medrxiv | 144 |
food intake | 143 |
light microscopy | 143 |
nanoparticle tracking | 143 |
per week | 143 |
respiratory infection | 143 |
membrane protein | 143 |
low level | 143 |
hcv infection | 143 |
results indicated | 143 |
healthy children | 143 |
experimental studies | 143 |
modifi ed | 143 |
congestive heart | 142 |
first months | 142 |
single nucleotide | 142 |
diagnostic tool | 142 |
pediatric intensive | 142 |
one third | 142 |
sequence analysis | 142 |
two days | 142 |
usual care | 142 |
blood count | 142 |
blood transfusions | 141 |
depressive symptoms | 141 |
structural changes | 141 |
associated infections | 141 |
health system | 141 |
early childhood | 141 |
daily living | 141 |
acid residues | 141 |
rbc transfusion | 141 |
psychological distress | 141 |
pivotal role | 141 |
underlying disease | 141 |
first group | 141 |
cell counts | 141 |
data set | 141 |
renal cell | 141 |
lower levels | 140 |
cells may | 140 |
care providers | 140 |
gene transfer | 140 |
tracking analysis | 140 |
good outcome | 140 |
relatively high | 140 |
point scale | 140 |
patient received | 140 |
cross sectional | 140 |
cardiogenic shock | 140 |
bl mice | 140 |
treatment option | 139 |
contrast agent | 139 |
spontaneous breathing | 139 |
imaging studies | 139 |
data regarding | 139 |
monte carlo | 139 |
head trauma | 139 |
receptor expression | 139 |
endotracheal tube | 139 |
allergic reactions | 139 |
first line | 139 |
study revealed | 139 |
converting enzyme | 138 |
surgery patients | 138 |
higher prevalence | 138 |
normal saline | 138 |
patient groups | 138 |
autologous blood | 138 |
vascular resistance | 138 |
patients reported | 138 |
myocardial perfusion | 138 |
cancer risk | 138 |
fev predicted | 138 |
quality assessment | 138 |
income countries | 138 |
significant positive | 138 |
significant role | 137 |
apoptotic cells | 137 |
circular dichroism | 137 |
alkaline phosphatase | 137 |
end stage | 137 |
mhc class | 137 |
demographic characteristics | 137 |
previously published | 137 |
often used | 137 |
crp levels | 137 |
czech republic | 137 |
exome sequencing | 137 |
patient data | 137 |
cognitive function | 137 |
candidate genes | 137 |
oxygen delivery | 137 |
tumor cell | 137 |
also evaluated | 136 |
bowel obstruction | 136 |
matched controls | 136 |
ang ii | 136 |
consecutive days | 136 |
upper airway | 136 |
protein interactions | 136 |
laboratory findings | 136 |
hemorrhagic shock | 136 |
wt mice | 135 |
different stages | 135 |
negative results | 135 |
insulin sensitivity | 135 |
additional studies | 135 |
contrast medium | 135 |
metastatic disease | 135 |
data suggests | 135 |
operating characteristic | 135 |
older patients | 135 |
chest wall | 135 |
emergency surgery | 135 |
clinical evaluation | 135 |
significant impact | 135 |
systemic inflammation | 135 |
limited data | 134 |
copyright holder | 134 |
subgroup analysis | 134 |
studies used | 134 |
patient died | 134 |
normal controls | 134 |
human plasma | 134 |
data extraction | 134 |
head ct | 134 |
studied patients | 134 |
health insurance | 134 |
also increased | 133 |
last year | 133 |
blood safety | 133 |
way anova | 133 |
side chain | 133 |
foreign body | 133 |
high concentrations | 133 |
peptide synthesis | 133 |
high fat | 133 |
weeks gestation | 133 |
epidemiological studies | 133 |
renal dysfunction | 133 |
independent predictors | 133 |
increasing number | 133 |
longitudinal study | 133 |
radiation therapy | 133 |
platelet activation | 132 |
normal values | 132 |
rbc units | 132 |
many cases | 132 |
prognostic factor | 132 |
social relations | 132 |
childhood asthma | 132 |
studies indicate | 132 |
ms patients | 132 |
nan title | 132 |
cell function | 132 |
mammary gland | 132 |
kidney transplantation | 132 |
factors affecting | 132 |
survival time | 132 |
chronic fatigue | 132 |
severe disease | 132 |
tested positive | 131 |
older age | 131 |
learning curve | 131 |
study provides | 131 |
vocal cord | 131 |
possible role | 131 |
molecular mechanism | 131 |
phase iii | 131 |
host disease | 131 |
enrolled patients | 131 |
various types | 131 |
preterm infants | 131 |
remained unchanged | 131 |
average time | 131 |
grip strength | 131 |
heat shock | 131 |
patient management | 131 |
within months | 131 |
urinary bladder | 131 |
lower limb | 131 |
susceptibility testing | 131 |
exclusion chromatography | 131 |
false negative | 130 |
studies show | 130 |
care professionals | 130 |
total body | 130 |
biologically active | 130 |
continuous infusion | 130 |
cantly higher | 130 |
arterial hypertension | 130 |
mr images | 130 |
therapeutic agents | 130 |
plasma exchange | 130 |
diagnostic value | 130 |
also associated | 130 |
probably due | 130 |
blood services | 130 |
inflammatory process | 130 |
pressure support | 130 |
metabolic acidosis | 130 |
one patients | 130 |
ct images | 130 |
interstitial lung | 130 |
stroke volume | 129 |
immunohistochemical staining | 129 |
adverse outcomes | 129 |
showed higher | 129 |
total cholesterol | 129 |
middle cerebral | 129 |
different levels | 129 |
brain regions | 129 |
still unclear | 129 |
health research | 129 |
bronchial epithelial | 129 |
light scattering | 129 |
provide evidence | 129 |
radical prostatectomy | 129 |
transfusion services | 128 |
arachidonic acid | 128 |
new method | 128 |
fi brosis | 128 |
like receptor | 128 |
vitro activity | 128 |
platelet function | 128 |
showed high | 128 |
biofilm formation | 128 |
therapeutic target | 128 |
medical research | 128 |
klebsiella pneumoniae | 128 |
two months | 128 |
blood component | 128 |
repeated measures | 128 |
clinical pharmacy | 128 |
evaluate whether | 128 |
different methods | 128 |
within one | 128 |
multidisciplinary team | 128 |
patients referred | 127 |
treatment response | 127 |
guinea pigs | 127 |
clinical care | 127 |
effi cacy | 127 |
last months | 127 |
airway obstruction | 127 |
investigated using | 127 |
different time | 127 |
grade iii | 127 |
showed increased | 127 |
including patients | 127 |
cell differentiation | 127 |
well documented | 127 |
folic acid | 127 |
increased incidence | 126 |
injured patients | 126 |
mainly due | 126 |
kg body | 126 |
chi square | 126 |
immunodeficiency virus | 126 |
one day | 126 |
cerebral cortex | 126 |
among others | 126 |
surface expression | 126 |
vein thrombosis | 126 |
pulmonary vascular | 126 |
salivary glands | 126 |
presentation will | 126 |
tbi patients | 126 |
missing data | 126 |
allergic diseases | 126 |
new approach | 126 |
sample sizes | 126 |
angiotensin ii | 126 |
experimental data | 126 |
year survival | 126 |
mammalian cells | 126 |
among women | 125 |
health effects | 125 |
physical performance | 125 |
pulmonary arterial | 125 |
well understood | 125 |
ion channels | 125 |
study groups | 125 |
preliminary study | 125 |
transplant patients | 125 |
positron emission | 125 |
hbv infection | 125 |
enzymatic activity | 125 |
assessment tool | 125 |
outcome data | 125 |
culture media | 125 |
immunocompromised patients | 125 |
drug use | 125 |
patients whose | 125 |
research center | 124 |
cellular uptake | 124 |
studies revealed | 124 |
imaging features | 124 |
will present | 124 |
treated group | 124 |
cerebral perfusion | 124 |
abdominal cavity | 124 |
cervical cancer | 124 |
also assessed | 124 |
cytokine release | 124 |
nosocomial infection | 124 |
accurate diagnosis | 124 |
take place | 124 |
risk group | 124 |
nerve injury | 124 |
drinking water | 124 |
infected cells | 123 |
studied using | 123 |
fluorescent protein | 123 |
chronic liver | 123 |
predictive factors | 123 |
cigarette smoke | 123 |
lactic acid | 123 |
invasive mechanical | 123 |
therapeutic strategies | 123 |
acute brain | 123 |
respiratory illness | 123 |
complication rates | 123 |
first week | 123 |
cell survival | 123 |
classified according | 123 |
traumatic stress | 123 |
allow us | 122 |
side effect | 122 |
needle aspiration | 122 |
severe ards | 122 |
also shown | 122 |
artery bypass | 122 |
qualitative study | 122 |
fio ratio | 122 |
quantitative pcr | 122 |
lipid profile | 122 |
bacterial growth | 122 |
control mice | 122 |
infectious complications | 122 |
descriptive study | 122 |
renal insufficiency | 122 |
lower extremity | 122 |
also present | 122 |
membrane oxygenation | 121 |
will include | 121 |
surgical icu | 121 |
retrospective observational | 121 |
median duration | 121 |
study investigated | 121 |
morphological changes | 121 |
complement activation | 121 |
preterm birth | 121 |
improve patient | 121 |
tertiary hospital | 121 |
lamina propria | 121 |
middle east | 121 |
intracranial hypertension | 121 |
first two | 121 |
total ige | 121 |
microglial cells | 121 |
tested using | 121 |
vascular disease | 121 |
two main | 121 |
significant risk | 121 |
control cells | 121 |
clinical efficacy | 121 |
written informed | 120 |
first report | 120 |
gastric mucosa | 120 |
invasive surgery | 120 |
tissue sections | 120 |
asthma symptoms | 120 |
highly expressed | 120 |
left ventricle | 120 |
highly sensitive | 120 |
stage i | 120 |
liver fibrosis | 120 |
information system | 120 |
rat brain | 120 |
high throughput | 120 |
hospital admissions | 120 |
good correlation | 120 |
national university | 120 |
working group | 120 |
cell populations | 120 |
emission tomography | 119 |
peritoneal dialysis | 119 |
energy expenditure | 119 |
average number | 119 |
cardiopulmonary bypass | 119 |
following treatment | 119 |
study including | 119 |
stable patients | 119 |
cognitive decline | 119 |
image analysis | 119 |
life threatening | 119 |
international guidelines | 119 |
muscle weakness | 119 |
emergency departments | 119 |
cd positive | 119 |
important roles | 119 |
breast carcinoma | 119 |
breast milk | 119 |
weighted imaging | 119 |
clinical assessment | 119 |
type mice | 119 |
basal ganglia | 119 |
national blood | 119 |
recurrence rate | 119 |
infrared spectroscopy | 119 |
study reported | 119 |
serine protease | 119 |
platelet transfusion | 118 |
treated mice | 118 |
different concentrations | 118 |
positive blood | 118 |
two distinct | 118 |
dynamics simulations | 118 |
influenza vaccination | 118 |
much lower | 118 |
surgical management | 118 |
enteral nutrition | 118 |
corticosteroid therapy | 118 |
lung volume | 118 |
ct imaging | 118 |
hiv aids | 118 |
identified patients | 118 |
whitney test | 118 |
recombinant human | 118 |
endothelial growth | 118 |
using spss | 118 |
asthma exacerbations | 117 |
guinea pig | 117 |
autosomal dominant | 117 |
massive transfusion | 117 |
small molecules | 117 |
cell membranes | 117 |
job crafting | 117 |
therapeutic effect | 117 |
respiratory viral | 117 |
iron deficiency | 117 |
remained stable | 117 |
study evaluated | 117 |
femoral head | 117 |
therapeutic potential | 117 |
samples collected | 117 |
open surgery | 117 |
related quality | 117 |
clinical pharmacist | 117 |
flow cytometric | 117 |
eff ects | 117 |
also measured | 117 |
infl uenza | 117 |
cancer therapy | 117 |
fat mass | 117 |
observation period | 117 |
primary objective | 117 |
free energy | 117 |
small molecule | 117 |
aneurysmal subarachnoid | 117 |
personal protective | 117 |
tissue injury | 117 |
antimicrobial peptides | 117 |
plasma cells | 117 |
four cases | 117 |
growth hormone | 116 |
clinical status | 116 |
extracorporeal membrane | 116 |
coumarin derivatives | 116 |
surgical site | 116 |
lung transplant | 116 |
slice thickness | 116 |
immunohistochemical analysis | 116 |
size distribution | 116 |
binding affinity | 116 |
data support | 116 |
particle size | 116 |
alcohol consumption | 116 |
solid tumors | 116 |
fatigue syndrome | 116 |
analysis will | 116 |
male rats | 116 |
right side | 116 |
ulcerative colitis | 116 |
control measures | 116 |
hong kong | 116 |
umbilical cord | 116 |
observational cohort | 116 |
molecular level | 116 |
action plan | 116 |
therapeutic approach | 116 |
medical icu | 116 |
often associated | 115 |
dose dependent | 115 |
regression analyses | 115 |
per group | 115 |
care services | 115 |
single molecule | 115 |
underwent laparoscopic | 115 |
normal subjects | 115 |
type iii | 115 |
highly conserved | 115 |
clinical history | 115 |
examined using | 115 |
eligible patients | 115 |
study drug | 115 |
coronary angiography | 115 |
size exclusion | 115 |
ed patients | 115 |
plasminogen activator | 115 |
positively associated | 115 |
positive effect | 115 |
patient outcome | 115 |
training program | 115 |
intravenous immunoglobulin | 115 |
functional status | 115 |
also included | 114 |
corpus callosum | 114 |
paraffin embedded | 114 |
control patients | 114 |
glucose metabolism | 114 |
vaccination uptake | 114 |
multiple regression | 114 |
high morbidity | 114 |
good clinical | 114 |
north america | 114 |
showed significantly | 114 |
complete remission | 114 |
biological processes | 114 |
eligibility criteria | 114 |
examination showed | 114 |
treated animals | 114 |
experimental study | 114 |
fluid balance | 114 |
million people | 114 |
neuronal activity | 114 |
hemolytic anemia | 114 |
jugular vein | 114 |
diagnostic imaging | 114 |
pancreatic cancer | 114 |
therapeutic targets | 114 |
grass pollen | 114 |
normal human | 114 |
prone position | 114 |
health service | 113 |
life support | 113 |
robotic surgery | 113 |
expression patterns | 113 |
version posted | 113 |
periodontal disease | 113 |
key words | 113 |
control animals | 113 |
single cell | 113 |
pcr assay | 113 |
infection rates | 113 |
healthcare providers | 113 |
drug interactions | 113 |
molecular basis | 113 |
several factors | 113 |
vivo studies | 113 |
ige levels | 113 |
based study | 113 |
may include | 113 |
antibody screening | 113 |
medication use | 113 |
salivary gland | 113 |
adverse effect | 113 |
nursing homes | 113 |
least months | 113 |
superoxide dismutase | 113 |
urine output | 113 |
takes place | 113 |
infectious agents | 113 |
treatment failure | 113 |
kg bw | 113 |
dose reduction | 113 |
antiglobulin test | 113 |
lipid bilayer | 112 |
social distancing | 112 |
therapeutic intervention | 112 |
results demonstrated | 112 |
dna binding | 112 |
lumbar spine | 112 |
cell carcinomas | 112 |
time consuming | 112 |
effect size | 112 |
long time | 112 |
procedure details | 112 |
patients years | 112 |
discharged home | 112 |
fusion protein | 112 |
node dissection | 112 |
remains unknown | 112 |
two hours | 112 |
significantly better | 112 |
eff ect | 112 |
crystal structure | 111 |
also studied | 111 |
new insights | 111 |
poor outcomes | 111 |
successfully treated | 111 |
standard treatment | 111 |
reperfusion injury | 111 |
cells treated | 111 |
cancer treatment | 111 |
severity scores | 111 |
treatment arms | 111 |
clinical decision | 111 |
asthma patients | 111 |
recently reported | 111 |
cellular processes | 111 |
local recurrence | 111 |
practice guidelines | 111 |
blood levels | 111 |
brain mri | 111 |
study results | 111 |
viral rna | 111 |
human lung | 111 |
retrospective case | 111 |
human serum | 111 |
ionizing radiation | 111 |
hazard ratio | 111 |
reference standard | 111 |
may allow | 111 |
hiatal hernia | 111 |
pathological conditions | 111 |
ct findings | 111 |
hela cells | 111 |
study designs | 111 |
factors influencing | 111 |
four studies | 111 |
showed similar | 111 |
inhibitory effects | 111 |
transforming growth | 111 |
randomized study | 110 |
per month | 110 |
malignant lesions | 110 |
estimated using | 110 |
immunosorbent assay | 110 |
health sciences | 110 |
group consisted | 110 |
target genes | 110 |
sentinel lymph | 110 |
hemodynamic parameters | 110 |
per unit | 110 |
two major | 110 |
care settings | 110 |
fully understood | 110 |
acid sequence | 110 |
general practitioners | 110 |
statistically different | 110 |
abdominal ct | 110 |
laboratory parameters | 110 |
left side | 110 |
viral replication | 110 |
likely due | 110 |
first day | 110 |
infection prevention | 109 |
fluid responsiveness | 109 |
cell wall | 109 |
findings may | 109 |
binding domain | 109 |
wall thickness | 109 |
male wistar | 109 |
risk stratification | 109 |
many different | 109 |
venous pressure | 109 |
patients experienced | 109 |
endothelial dysfunction | 109 |
days following | 109 |
may indicate | 109 |
proteins involved | 109 |
glycemic control | 109 |
significant higher | 109 |
important cause | 109 |
indocyanine green | 109 |
human immunodeficiency | 109 |
results patients | 109 |
coronary arteries | 109 |
cell therapy | 109 |
diff erent | 109 |
title abstract | 109 |
abcd study | 109 |
strong correlation | 109 |
bloodstream infection | 109 |
medication adherence | 109 |
expression pattern | 109 |
hek cells | 109 |
additional file | 109 |
kidney function | 108 |
affi nity | 108 |
examine whether | 108 |
early phase | 108 |
toxic effects | 108 |
seven days | 108 |
multivariable logistic | 108 |
mice showed | 108 |
least days | 108 |
different cell | 108 |
drug resistant | 108 |
available data | 108 |
socioeconomic status | 108 |
group iii | 108 |
many years | 108 |
bloodstream infections | 108 |
symptom onset | 108 |
contrast media | 108 |
treatment strategies | 108 |
cardiopulmonary resuscitation | 108 |
immune function | 108 |
abdominal trauma | 108 |
clinical suspicion | 108 |
limited number | 108 |
helicobacter pylori | 108 |
search strategy | 108 |
hip fracture | 108 |
gene encoding | 108 |
exogenous ncrnas | 107 |
broad range | 107 |
oxygen therapy | 107 |
genetic factors | 107 |
patients enrolled | 107 |
paediatric patients | 107 |
mean score | 107 |
studies demonstrated | 107 |
made available | 107 |
th cells | 107 |
influenza vaccine | 107 |
blood centers | 107 |
surgical technique | 107 |
less common | 107 |
mechanisms involved | 107 |
brain tumors | 107 |
postoperative pain | 107 |
review board | 107 |
authors declare | 107 |
using data | 107 |
may require | 107 |
fev fvc | 107 |
cell biology | 107 |
lipid metabolism | 107 |
specific cd | 107 |
higher number | 107 |
human brain | 107 |
major complications | 107 |
lower risk | 107 |
care setting | 106 |
previous work | 106 |
coupled receptors | 106 |
novel therapeutic | 106 |
coronary heart | 106 |
also investigated | 106 |
signalling pathways | 106 |
cirrhotic patients | 106 |
different groups | 106 |
mitochondrial dysfunction | 106 |
genes encoding | 106 |
specifi city | 106 |
expression profiles | 106 |
patients infected | 106 |
density gradient | 106 |
low concentrations | 106 |
acinetobacter baumannii | 106 |
prospective randomized | 106 |
factors may | 106 |
drug therapy | 106 |
copy number | 106 |
also identified | 106 |
retinal vein | 106 |
functional outcomes | 106 |
statistically significantly | 106 |
retrospectively analyzed | 106 |
enteral feeding | 106 |
term care | 105 |
effi ciency | 105 |
younger age | 105 |
bacterial pathogens | 105 |
negative patients | 105 |
mental status | 105 |
results support | 105 |
energy transfer | 105 |
using flow | 105 |
largely unknown | 105 |
previous research | 105 |
previous reports | 105 |
within normal | 105 |
wide spectrum | 105 |
higher level | 105 |
medication reconciliation | 105 |
antiviral activity | 105 |
may suggest | 105 |
continuous variables | 105 |
qualitative research | 105 |
hours later | 105 |
fatty liver | 105 |
donor selection | 105 |
individual patient | 105 |
inguinal hernia | 105 |
analysis demonstrated | 105 |
antibody responses | 105 |
adrenergic receptor | 104 |
young people | 104 |
allergic asthma | 104 |
oxide synthase | 104 |
respiratory diseases | 104 |
oral cavity | 104 |
middle ear | 104 |
blood groups | 104 |
early onset | 104 |
social isolation | 104 |
amniotic fluid | 104 |
institutional review | 104 |
currently used | 104 |
low birth | 104 |
mean length | 104 |
air quality | 104 |
results suggested | 104 |
house dust | 104 |
cardiovascular events | 104 |
remains controversial | 104 |
multiple myeloma | 104 |
cord injury | 104 |
cell population | 104 |
neural stem | 104 |
respiratory pathogens | 104 |
severe traumatic | 104 |
nkt cells | 104 |
without significant | 104 |
supine position | 104 |
plasma glucose | 104 |
research project | 104 |
premature infants | 104 |
surface markers | 103 |
lower limbs | 103 |
young patients | 103 |
descriptive abstract | 103 |
respiratory function | 103 |
blood service | 103 |
oxygen consumption | 103 |
autoimmune disease | 103 |
results revealed | 103 |
may benefit | 103 |
also demonstrated | 103 |
barrier function | 103 |
lymphoblastic leukemia | 103 |
cox regression | 103 |
clinical applications | 103 |
venous access | 103 |
renal impairment | 103 |
weeks later | 103 |
examined whether | 103 |
results provide | 103 |
protein intake | 103 |
ml vs | 103 |
results may | 102 |
care hospital | 102 |
immune complexes | 102 |
thyroid carcinoma | 102 |
respiratory support | 102 |
well described | 102 |
negative impact | 102 |
method using | 102 |
natural killer | 102 |
biopsy specimens | 102 |
obstructive sleep | 102 |
acute lymphoblastic | 102 |
left atrial | 102 |
day post | 102 |
fungal infections | 102 |
therapeutic strategy | 102 |
kidney transplant | 102 |
study suggest | 102 |
highly variable | 101 |
screening tool | 101 |
research group | 101 |
inferior vena | 101 |
contrast agents | 101 |
also tested | 101 |
will receive | 101 |
best practice | 101 |
fluid resuscitation | 101 |
increasing evidence | 101 |
will focus | 101 |
ten years | 101 |
plasma concentration | 101 |
based approach | 101 |
health promotion | 101 |
clinical samples | 101 |
allergic disease | 101 |
inflammatory processes | 101 |
highly significant | 101 |
also determined | 101 |
weighted images | 101 |
macular degeneration | 101 |
growth rate | 101 |
biological activities | 101 |
airway smooth | 101 |
full length | 101 |
treatment period | 101 |
human studies | 101 |
bone mineral | 101 |
chronic respiratory | 101 |
complete blood | 101 |
liver tissue | 101 |
will need | 101 |
cervical spine | 101 |
common complication | 101 |
adverse drug | 100 |
stage iii | 100 |
cells using | 100 |
clinical settings | 100 |
collected using | 100 |
cant diff | 100 |
right ventricle | 100 |
total score | 100 |
pain management | 100 |
nmda receptor | 100 |
persistent asthma | 100 |
herpes simplex | 100 |
care system | 100 |
focus group | 100 |
liver enzymes | 100 |
elevated serum | 100 |
common cold | 100 |
south africa | 100 |
identifi cation | 100 |
vitro model | 100 |
previously demonstrated | 100 |
within weeks | 100 |
correct diagnosis | 100 |
specific primers | 100 |
icu los | 100 |
host cell | 100 |
carbon monoxide | 100 |
lung transplantation | 100 |
significant negative | 100 |
based studies | 100 |
positive result | 100 |
protease inhibitors | 100 |
negative control | 100 |
zika virus | 100 |
positive cases | 100 |
significant morbidity | 100 |
two hundred | 99 |
standard deviations | 99 |
years later | 99 |
drug development | 99 |
post operative | 99 |
first years | 99 |
prefrontal cortex | 99 |
cell receptor | 99 |
every hours | 99 |
controlled clinical | 99 |
terminal domain | 99 |
using high | 99 |
ed visits | 99 |
also examined | 99 |
aortic valve | 99 |
protein structure | 99 |
methods used | 99 |
longer duration | 99 |
powerful tool | 99 |
several years | 99 |
rights reserved | 99 |
neonatal intensive | 99 |
strains isolated | 99 |
following parameters | 99 |
atomic force | 99 |
nk cell | 99 |
pcr analysis | 99 |
gamma camera | 99 |
time interval | 99 |
protein folding | 99 |
quality listening | 99 |
high number | 99 |
risk groups | 98 |
task force | 98 |
diagnostic tests | 98 |
vein occlusion | 98 |
early postoperative | 98 |
nasal polyps | 98 |
made using | 98 |
sex ratio | 98 |
four weeks | 98 |
two decades | 98 |
steroid therapy | 98 |
color doppler | 98 |
urinary incontinence | 98 |
lopinavir ritonavir | 98 |
fine needle | 98 |
tumor suppressor | 98 |
large scale | 98 |
catheter insertion | 98 |
ultrasound examination | 98 |
one hand | 98 |
reported cases | 98 |
promising results | 98 |
ventilatory support | 98 |
dna sequencing | 98 |
term effects | 98 |
medical therapy | 97 |
well defined | 97 |
increasingly used | 97 |
dust mite | 97 |
care facilities | 97 |
human health | 97 |
newly developed | 97 |
basement membrane | 97 |
acute coronary | 97 |
studies conducted | 97 |
benefi ts | 97 |
greater risk | 97 |
portal hypertension | 97 |
safety profile | 97 |
linked immunosorbent | 97 |
published studies | 97 |
grade i | 97 |
cd cell | 97 |
diagnostic performance | 97 |
bovine serum | 97 |
venous thromboembolism | 97 |
human genome | 97 |
anastomotic leak | 97 |
major surgery | 96 |
organ donation | 96 |
epidermal growth | 96 |
murine model | 96 |
diastolic blood | 96 |
spiral ct | 96 |
early life | 96 |
lavage fluid | 96 |
nursing home | 96 |
mean bmi | 96 |
therapeutic options | 96 |
negatively charged | 96 |
hemodynamic instability | 96 |
interventional radiology | 96 |
clinical application | 96 |
early treatment | 96 |
correlation coefficients | 96 |
high blood | 96 |
specific antibody | 96 |
clinical impact | 96 |
clinical evidence | 96 |
blunt trauma | 96 |
nmr spectroscopy | 96 |
postoperative course | 96 |
derived exosomes | 96 |
usa introduction | 96 |
side chains | 96 |
patients completed | 96 |
host immune | 96 |
wound infection | 96 |
inflammatory disease | 96 |
antibiotic prophylaxis | 96 |
full text | 96 |
rats treated | 96 |
categorical variables | 96 |
post hoc | 96 |
upper gi | 96 |
prick test | 95 |
without evidence | 95 |
least three | 95 |
quantitative real | 95 |
allergic patients | 95 |
mice treated | 95 |
cell response | 95 |
immune cell | 95 |
every day | 95 |
serum level | 95 |
energy metabolism | 95 |
see also | 95 |
per se | 95 |
effect sizes | 95 |
antibacterial activity | 95 |
significant relationship | 95 |
differential expression | 95 |
estrogen receptor | 95 |
intravenous administration | 95 |
recombinant protein | 95 |
effects model | 95 |
unclear whether | 95 |
receive either | 95 |
stage ii | 95 |
ill children | 95 |
median survival | 95 |
underwent surgery | 95 |
antiretroviral therapy | 95 |
diff erences | 95 |
risk perception | 95 |
evidence based | 95 |
slightly higher | 95 |
interstitial pneumonia | 95 |
stress response | 95 |
goblet cell | 94 |
incidence rates | 94 |
acute stroke | 94 |
university hospitals | 94 |
also detected | 94 |
may present | 94 |
effective method | 94 |
one group | 94 |
play important | 94 |
past medical | 94 |
clinical conditions | 94 |
wilcoxon signed | 94 |
median number | 94 |
cause mortality | 94 |
significant proportion | 94 |
good results | 94 |
pulmonary infection | 94 |
four times | 94 |
gastroesophageal reflux | 94 |
less frequent | 94 |
cases showed | 94 |
dorsal root | 94 |
conditioned medium | 94 |
social networks | 94 |
transfusion therapy | 94 |
pet imaging | 94 |
months follow | 94 |
two consecutive | 94 |
study performed | 94 |
like cells | 94 |
months prior | 94 |
human disease | 94 |
expression profile | 94 |
likert scale | 94 |
lung diseases | 94 |
spect ct | 94 |
disease process | 94 |
physical function | 94 |
essential role | 94 |
biological effects | 94 |
mean fev | 94 |
lesser extent | 94 |
developmental delay | 94 |